Genetics and epilepsy by Steinlein, Ortrud K.
pilepsy is one of the most common and het-
erogeneous neurological conditions,and the molecular
pathomechanisms underlying the different seizure dis-
orders have now been studied intensively for more than
two decades.
1 There exists a large group of epilepsies
that are often labeled as symptomatic, in order to dis-
tinguish them from the idiopathic epilepsies that are
believed to be mainly of genetic origin. However, with
the progress in genetic analysis,it has become more and
more obvious that no clear division exists between the
two groups of epilepsies.Findings such as SCN1A muta-
tions underlying severe myoclonic epilepsy of infancy
(SMEI), an epilepsy syndrome that was formerly
labeled as symptomatic, as well as the failure to find
major genes for common idiopathic epilepsies such as
juvenile myoclonic epilepsy, raise questions about the
usefulness of a strict classification that distinguishes
between symptomatic and idiopathic cases.In the etiol-
ogy of most epilepsies, a combination of acquired and
genetic factors is involved,while predominantly genetic
epilepsies constitute only a minority of all seizure dis-
orders (Figure 1).
2 The latter nevertheless serve as an
important source for our increasing knowledge about
the genes and gene families that can be involved in
epileptogenesis, and help us gain insight into the path-
omechanisms underlying the more common forms of
epilepsy. In the following paragraphs, examples of
seizure syndromes are described that are representative
of the different genetic mechanisms in epileptogenesis
known today. These include ion-channel disorders,
examples of the different mechanisms underlying pro-
gressive myoclonus epilepsies,a group of neurogenetic
disorders that can be due to either developmental
abnormality,and defects in energy metabolism or meta-
bolic disturbances,as well as neuronal migration disor-
ders.
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The term “epilepsy” describes a heterogeneous group of
disorders, most of them caused by interactions between
several or even many genes and environmental factors.
Much rarer are the genetic epilepsies that are due to sin-
gle-gene mutations or defined structural chromosomal
aberrations, such as microdeletions. The discovery of sev-
eral of the genes underlying these rare genetic epilep-
sies has already considerably contributed to our under-
standing of the basic mechanisms in epileptogenesis. The
progress made in the last 15 years in the genetics of epi-
lepsy is providing new possibilities for diagnosis and
therapy. Here, different genetic epilepsies are reviewed
as examples, to demonstrate the various pathways that
can lead from genes to seizures.   
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Dysfunctions of mutated voltage- or ligand-gated ion
channels have been shown to be a major cause of idio-
pathic epilepsies,at least in the rare genetic forms (Table
I).The detailed genetic and electrophysiological analy-
ses of different ion channels have provided significant
knowledge on the pathophysiological pathways leading
from mutation to seizures.
3 Ion-channel mutations are a
known cause of rare monogenic idiopathic epilepsies,but
are also suspected to play a major role in more common
epilepsies such as juvenile myoclonic epilepsy or child-
hood and juvenile absence epilepsies. In the following
paragraphs, some monogenic epilepsies have been
selected as examples,to illustrate the importance of ion
channels in epileptogenesis.
Familial nocturnal frontal lobe epilepsy
The gene for autosomal dominant nocturnal frontal lobe
epilepsy (ADNFLE) was the first one described for an
inherited form of idiopathic epilepsy.The mean age of
onset in ADNFLE is during adolescence or young adult-
hood,with considerable intra- and interfamilial variance.
Most mutations (with the exception of low penetrance
mutation I312M) demonstrate a penetrance of 70% to
80%.The clusters of brief motor seizures that are typical
of ADNFLE occur mostly out of nonREM (rapid eye
movement) sleep.Patients often have recurrent parox-
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Selected abbreviations and acronyms
ADNFLE autosomal dominant nocturnal frontal lobe
epilepsy
BFIC benign familial infantile convulsions
BFNC benign familial neonatal convulsions
CLN neuronal ceroid lipofuscinoses
EPM1 epilepsy progressive myoclonus (Unverricht-
Lundborg disease)
GEFS+ generalized epilepsy with febrile seizures plus
MERRF myoclonic epilepsy and ragged-red fiber disease
nAChR nicotinic acetylcholine receptor
SMEI severe myoclonic epilepsy of infancy
TM transmembrane regions
Figure 1. Schematic representation of genetic and nongenetic etiologies
in epilepsy. 
Epilepsies
Common
Rare
Polygenic
Mendelian inheritance Nonmendelian inheritance
Mitochondrial inheritance
Chromosomal aberrations
Autosomal dominant
Autosomal recessive
X-chromosomal dominant
X-chromosomal  recessive
Oligogenic
Table I. Genes in idiopathic epilepsy. AD, autosomal dominant; OG, oligogen; (AD), rare families with monogenic inheritance have been described
Abbreviation Syndrome Gene(s) Chromosome Mode of inheritance
ADNFLE Autosomal dominant nocturnal frontal lobe epilepsy CHRNA4 20q13.3 AD
CHRNB2 1q21
BFNC Benign familial neonatal convulsions KCNQ2 20q13.3 AD
KCNQ3 8q24
BFNIS Benign familial neonatal-infantile seizures SCN2A 2q24 AD
GEFS+ Generalized epilepsy with febrile seizures plus SCN1A 2q24 AD, OG
SCN2A 2q24
SCN2B 11q23
GABRG2 5q31.1-q33.1
SMEI Severe myoclonic epilepsy of infancy SCN1A 2q24 AD, OG
JME Autosomal dominant juvenile myoclonic epilepsy GABRA1 5q34-q35 OG, (AD)
CACNB4 2q22-q23
CLCN2 3q26
EJM1 Juvenile myoclonic epilepsy type 1 EFHC1 6p12-p11 AD
ADPEAF Autosomal dominant epilepsy with auditory features LGI1 10q24 ADysmal awakenings associated with stereotyped move-
ments.Most seizure episodes are of 2 to 20 s duration,but
some of them might last considerably longer.In sleep-
walking periods, patients might move around, speak
unintelligibly, or scream for 3 min or more. Patients
report aura phenomena including epigastric,sensory,or
psychic symptoms that often precede the seizures.A typ-
ical seizure starts with gasps,grunts,or vocalizations fol-
lowed by thrashing hyperkinetic activity or tonic stiffen-
ing of the limbs,and superimposed clonic jerking.Many
patients are,at least initially,not aware of their seizures,
or they underestimate their number of seizures per night.
Typical complaints are tiredness during daytime and poor
sleep quality.Treatment with antiepileptic drugs such as
carbamazepine is effective with respect to seizure con-
trol or reduction in many,but not all,patients.
4
In 1995 a first mutation was identified in the CHRNA4
gene as the underlying cause in a large Australian
ADNFLE family that previously helped to map the dis-
order to chromosome 20q13.3.
5 Since then, additional
CHRNA4 mutations, as well as mutations in two addi-
tional genes (CHRNB2,CHRNA2),have been found in
sleep-related frontal lobe epilepsy.
6-8 CHRNA4,CHRNA2,
and CHRNB2 encode the α4- and β2-subunits of the neu-
ronal nicotinic acetylcholine receptor (nAChR),respec-
tively.The nAChRs are members of the large family of lig-
and-gated ion channels.They are characterized by five
(identical or different) homologous subunits that assem-
ble around a central axis and form a cation-selective ion
channel. With the exception of CHRNB2-I312M the
known ADNFLE mutations in either CHRNA4 or
CHRNB2 are located within the second transmembrane
domain. The second transmembrane (and in parts the
third) domain mainly builds the walls of the ion channel;
thus,it seems that ADNFLE mutations specifically target
the channel’s gating structure.Until now,four CHRNA4
and three CHRNB2 mutations have been described in
ADNFLE families from different parts of the world.Most
interesting are those mutations that have occurred inde-
pendently in different families, because they offer the
opportunity to study the effects genetic backgrounds
might have on the clinical expression of the disorder.
9
Not surprisingly in view of the important role of the
cholinergic system in higher brain functions, there has
been evidence presented that at least some ADNFLE
mutations not only cause epilepsy but are also associated
with other neurological disorders or cognitive deficits.A
good example is presented by the Norwegian ADNFLE
family carrying the CHRNA4-776ins3 mutation.
10,11 More
than half of the 11 mutation carriers are affected by either
schizophrenia, negative symptoms of schizophrenia, or
severe apathy.Another ADNFLE mutation,CHRNA4-
S252L,is associated with mental retardation and/or behav-
ioral problems in two families of different geographic ori-
gin. In the latter families the differences in geographic
origin strongly suggest that the cognitive deficits are
caused by the mutation rather than by unrelated factors.
8
Most of the known ADNFLE mutations have already
been studied in different expression systems.They typi-
cally display an increased sensitivity for the natural ago-
nist acetylcholine,demonstrated by a shift of the agonist
response curve to the left. Thus, the pathomechanism
caused by these mutations seems to be based on a gain-
of-function effect that is likely to increase ion flow
through the channel pore. Furthermore, comparison
between the mutations showed that they are character-
ized by different biopharmacological profiles.For exam-
ple,reduced calcium permeability was observed for the
mutants CHRNA4-S248F and CHRNA4-776ins3 but not
for the CHRNA4-S252L mutation.It is tempting to spec-
ulate that the particular functional signatures of each
mutant contribute to the abovementioned observations
of associated neurological features or cognitive defects
in ADNFLE,while the gain-of-function effect might be
responsible for the epilepsy phenotype itself.
12
It has been hypothized that in presynaptically located
nAChRs the gain-of-function effect might activate
inhibitory γ-aminobutyric acid (GABA)ergic interneu-
rons.Such interneurons have an important role in con-
trolling the activity of neuronal networks in brain struc-
tures such as neocortex and hippocampus by
synchronizing the firing of the participating neurons.An
enhanced GABA release would first inhibit a larger
number of pyramidal cells than usual. After recovery
from inhibition,the sudden enhancement in network syn-
chrony could eventually cause the pathological hyper-
synchronization that might give rise to a seizure.
Benign familial neonatal convulsions 
Benign familial neonatal convulsions (BFNC) is an auto-
somal dominantly inherited seizure disorder of the new-
born.BFNC is characterized by an age of onset between
the first day and,at latest,the fourth month of life.The
seizures are mostly unprovoked,generalized,or multi-
focal,and of the tonic and/or clonic type.They are often
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31accompanied by dyspnea, ocular symptoms, or other
autonomic signs.The course of the disorder is usually
benign and self-limiting, and, with or without pharma-
cotherapy,in the majority of patients the seizures remit
spontaneously within a few days or weeks.Most patients
are seizure-free by the age of 6 months.
13 Later in life
seizures can reoccur in about 10% to 15% of the patients,
starting mostly at school age or in young adulthood.
These late-onset seizures are often provoked,for exam-
ple,by lack of sleep.Recently,it has become a point of
discussion as to whether the term “benign” should be
used to describe the course of the disorder,since several
BFNC families have come to attention in which some or
all of the patients had a less than benign outcome.These
patients often show a higher frequency of seizures and
are often not seizure-free after the age of 4 months.Two
BFNC families have been described in which a mutation
carrier developed drug-resistant seizures and/or epilep-
tic encephalopathy shortly after birth,resulting in severe
psychomotor retardation.
14,15 Follow-up studies showed
that even patients that have formerly been believed to
have a benign course of the disorder later often showed
moderate delays of psychomotor development.
Mutations in the voltage gated potassium channel genes
KCNQ2 (chromosome 20q13.3) and (more rarely)
KCNQ3 (chromosome 8q24) have been described in dif-
ferent BFNC families.
16-18 Both genes encode channel
subunits with identical structures including six trans-
membrane regions (TM),a voltage sensor in TM4,a loop
between TM5 and TM6 that builds the ion channel pore,
and a long C-terminal region that contains sequence
motifs for subunit assembling.So far more than 40 muta-
tions have been reported for KCNQ2 and three for
KCNQ3.The BFNC mutations are either missense muta-
tions located in one of the TMs, truncating mutations
(nonsense,insertion/deletions or splice site mutations),
or large deletions.The majority of mutations are private,
ie,they have not been found in other BFNC families.
The ion channel encoded by KCNQ2 and KCNQ3 pro-
vides one of the major physical equivalents of the so-
called M-current,a potassium current which is known to
be a powerful controller of neuronal firing.M-currents
regulate the frequency with which action potentials are
built by opposing sustained membrane depolarization.
They have a pivotal role in the stabilization of membrane
potentials, and are therefore in a powerful position to
control excess neuronal excitability and prevent
seizures.
19 Given this important role in brain excitability,
it is not surprising that BFNC mutations were shown to
cause only modest reductions (20% to 30%) in potas-
sium currents in reconstitution experiments.Even such
slight alterations of M-channel activity are obviously suf-
ficient to increase seizure susceptibility in affected new-
borns.
20 Only a few KCNQ2 mutations have been identi-
fied that, at least in reconstitution experiments, had a
dominant negative effect on channel function,ie,reduced
the current by more than 50%.One of these mutations
is the R207W amino acid exchange in KCNQ2 that
causes both BFNC and myokymia, a spontaneous and
repetitive involuntary contraction of muscle fiber groups.
In the BFNC/myokymia syndrome the occurrence of
both central and peripheral neurological symptoms
might be explained by the unusual electrophysiological
profile of the underlying mutation.The magnitude in loss
of current observed for R207W depends strongly on the
pattern and time course of depolarization.It is therefore
possible that the unusual dominant negative effect of
R207W establishes itself only in the peripheral nervous
system,causing symptoms like myokymia.
21
Infantile convulsion syndromes 
Benign familial infantile convulsions (BFIC) is an autoso-
mal dominantly inherited partial epilepsy syndrome of
early childhood.
22 Seizures usually start between months 4
and 6,with remission before the age of 3 years.The partial
seizures occur in clusters and usually respond well to
antiepileptic drug treatment.BFIC is genetically hetero-
geneous, and has been linked to loci on chromosomes
1q23, 2q24, 19q, and 16p12-q12 in various families.
Interestingly,three other disorders with overlapping neu-
rological features map to the candidate region on chro-
mosome 16p12-q12,including the infantile convulsions and
choreoathetosis syndrome (ICCA;OMIM 602066),parox-
ysmal kinesigenic choreoathetosis (PKC;OMIM 128200),
and a syndrome comprising rolandic epilepsy,paroxysmal
exercise-induced dystonia,and writer's cramp (EPRPDC;
OMIM 608105).Another rare seizure disorder with an age
of onset intermediate between BFNC and BFIC is benign
familial neonatal/infantile convulsions (BFNIC). In
BFNIC both neonatal and early infantile onsets of the
seizures can be present in the same family. BFNIC has
been shown to be caused by mutations in the voltage-
gated sodium channel subunit gene SCN2A,a gene that is
also discussed as a minor gene for generalized epilepsy
with febrile seizures plus (GEFS+).
23
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32Febrile seizures, generalized epilepsy with febrile
seizures plus, and Dravet syndrome 
Febrile seizures are the most common seizure type in
humans;they affect 5% to 10% of children under the age
of 6 years.In most patients an oligo- or polygenic back-
ground rather than a monogenic cause of the seizures is
assumed.Rare families with an apparent autosomal dom-
inant mode of inheritance have been identified,and sev-
eral putative gene loci described.These tentative gene
locations include FEB1 on chromosome 8q13-q21,FEB2
on 19p,FEB3 on 2q23-q24,FEB4 on 5q14-q15,FEB5 on
6q22-q24,and FEB6 on 18p11.2.
In some families febrile seizures may persist beyond the
age of 6 years and/or may be associated with variable
afebrile seizures (febrile seizures plus).This probably not
so rare syndrome has been named generalized epilepsy
with febrile seizures plus (GEFS+). Afebrile seizure
types in GEFS+ individuals include generalized tonic-
clonic seizures,myoclonic,absence,and atonic seizures,
and in some patients also partial seizures.
24The mode of
inheritance underlying GEFS+ is still a matter of debate.
Although in some families the trait is likely to be auto-
somal dominant,in others it is probably better described
as oligogenic or as a major gene effect.A genetic concept
involving more than one gene would also better fit to the
observed clinical variability in GEFS+.Several different
ion channel genes have been implicated in GEFS+—
SCN1B,SCN1A,SCN2A,GABRG2—but in most fam-
ilies the underlying mutation(s) remain elusive.The first
GEFS+ mutation was identified in the SCN1B gene on
chromosome 19q13.1,a gene that encodes an accessory
subunit of the voltage gated sodium channel.
25
Nevertheless,most of the mutations identified since then
were found in the SCN1A gene,one of the genes coding
for the major, pore-forming α-subunit of the voltage
gated sodium channel.
2These α-subunits are composed
of four domains each containing six TM (TM1-TM6),and
the SCN1A mutations are distributed over the whole
length of this large gene.
26
Mutations in the SCN1A gene have also been identified in
patients with SMEI (also known as Dravet syndrome) and
in the phenotypically overlapping syndromes of border-
line SMEI (SMEB) or intractable childhood epilepsy with
generalized tonic-clonic seizures (ICEGTC).
27The clinical
phenotype of SMEI is characterized by an initially normal
psychomotor development,onset of febrile seizures within
the first year of life,and subsequent manifestation of var-
ious afebrile seizure types including absence,myoclonic,
and partial seizures.Pharmacoresistant seizures and devel-
opmental delay become manifest during the second year
of life.Nearly all reported SMEI mutations are de novo,
and they are often truncating and/or located in function-
ally critical parts of the gene,while GEFS
+ mutations are
mostly found in less highly conserved parts of SCN1A.It
is therefore likely that SMEI and GEFS
+ mutations differ
with respect to their predicted impact on ion channel func-
tion,explaining the differences in clinical severity between
both syndromes.
Expression experiments with different SMEI and GEFS
+
mutations have shown,probably due to different exper-
imental setups, a variety of biophysical aberrations,
including complete loss-of-function,altered gating prop-
erties, or even gain-of-function effects.Thus, the exact
functional effects of SMEI and GEFS
+ mutations and
their correlations to clinical phenotypes are still unclear.
28
Non-ion channel genes in idiopathic epilepsy
Most of the epilepsy genes mentioned so far code for var-
ious ion channels,or for proteins that modulate ion-chan-
nel function (eg,accessory channel subunits).This has led
to the assumption that idiopathic epilepsies are a group
of channelopathies. However, in 2001 it was dem-
onstrated that non-ion channel genes play at least a
minor role in the etiology of idiopathic epilepsies.
Mutations in the LGI1 gene (leucine-rich glioma inacti-
vated gene 1) have been shown to be a cause of autoso-
mal dominant partial epilepsy with auditory features
(AD-PEAF), also called autosomal dominant lateral
temporal lobe epilepsy.
29This rare syndrome is charac-
terized by simple partial seizures with mainly acoustic
and sometimes also visual hallucinations.
30 Some families
have been described in which the seizures tend to start
with a brief sensory aphasia without reduced conscious-
ness.
31 The mutational spectrum known for the LGI1
gene on chromosome 10q24 includes both missense
mutations and truncating mutations.So far,not much is
known about the function of the LGI1 gene,which codes
for a protein characterized by a leucine-rich repeat motif
(LRR) in its N-terminal end and seven so-called
epilepsy-associated repeats (EARs) in the C-terminal
half.The LRR motif is found mostly in proteins that par-
ticipate in some kind of protein-protein interaction or
receptor function.
32,33Two recently published articles have
shed some light on the possible function of LGI1 protein
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33in human brain.They were able to show that two differ-
ent isoforms of LGI1 protein are expressed in brain,with
a long isoform that is secreted and a short isoform that is
retained in the intracellular compartment.In the exper-
imental setup the secreted isoform of LGI1 binds to dif-
ferentiated PC12 cells,suggesting that a LGI1-specific
receptor complex is present on these cells.A putative
receptor for LGI1 has been identified in ADAM22, a
trans-membrane protein anchored to the postsynaptic
density-95 (PSD-95)-associated protein complex by
stargazin.
34 Both ADAM22 and stargazin are genetically
linked to epilepsy, at least in knockout animal models.
The PSD-95 protein complex has a scaffolding function
at excitatory synapses and is involved in both synapto-
genesis and synaptic plasticity.It controls synaptic AMPA
receptor surface expression,and the number of expressed
receptors could be significantly increased by LGI1
expression in cultured hippocampal neurons. Thus,
ADPEAF mutations might cause epilepsy by interfering
with the protein-protein interaction between LGI1 and
ADAM22,causing a dysregulation of synaptic transmis-
sion.
34 Additional non-ion channel genes have been
described in epilepsy families since LGI1 was first
reported several years ago. Examples are the EFHC1
gene and the MASS1/VLGR1 gene,but so far the respec-
tive initial reports have not been confirmed in indepen-
dent studies.
35
Progressive myoclonus epilepsies 
Numerous neurogenetic syndromes are known in which
seizures are a predominant feature but are usually
accompanied by other neurological or non-neurological
symptoms.The genetic causes (and therefore the path-
ways leading to epilepsy) found in these disorders are
more diverse than those described above for idiopathic
epilepsies.Mutated genes might be involved in many dif-
ferent functions, such as metabolic disturbances, mito-
chondrial dysfunction,or aberrant neuronal (precursor)
cell migration.The heterogeneous group of progressive
myoclonus epilepsies that includes Unverricht-Lundborg
disease (Baltic myoclonus), myoclonic epilepsy and
ragged-red fiber disease (MERRF),neuronal ceroid lipo-
fuscinosis (CLN),dentatorubropallidoluysian atrophy,
Gaucher disease,Lafora disease,and sialidosis,is repre-
sentative of the various mechanisms that might underlie
different neurogenetic syndromes characterized pre-
dominantly by seizures and cognitive decline.Some of
these syndromes are therefore discussed in more detail
in the following sections.
Unverricht-Lundborg disease
Unverricht-Lundborg disease (EPM1, also known as
Baltic or Mediterranean myoclonus epilepsy) is a typical
example of a progressive myoclonus epilepsy character-
ized by generalized epileptic seizures, myoclonus (brief
contraction of a muscle or a group of muscles),and pro-
gressive neurological deterioration including ataxia and
dementia.EPM1,the most common form of progressive
myoclonus epilepsy,is an autosomal recessive neurode-
generative disorder with an age of onset between 6 and 18
years.Severe stimulus-sensitive myoclonus and general-
ized tonic-clonic seizures are the main features;addition-
ally,mental deterioration,intention tremor,dysarthria,and
mild ataxia may develop in later stages of the disorder.So
far a few point mutations in the CSTB gene (cystatin B,
also stefin B) on chromosome 21q22.3 have been identi-
fied in different EPM1 patients (Table II).However,in the
majority of patients the disorder is caused by an unstable
expansion of a dodecamer repeat located in the 5' flank-
ing region of the CSTB gene.
36 Expansion of the repeat
causes absence of,or greatly reduced,CSTB expression;
thus, a loss-of-function effect is a key event in EPM1
Basic research
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Table II. Cystatin B mutations in Unverricht-Lundborg disease. *different nucleotide numbering
Mutation Predicted effects
Dodecamer repeat expansion Disruption of promotor function, resulting in reduction of mRNA expression
426G>C Amino acid exchange at codon 4, affects contact of cystatin B with papain
149G>A* Amino acid exchange at codon 50
168+1_18del* Intronic deletion affecting splicing
1925G>C Abnormal splicing of pre-mRNA
2353A>G Abnormal splicing of pre-mRNA
2388T>C Stop codon mutation at codon 75, causing RNA decay or protein truncation
del2400TC Frame shift leading to premature stop codon at codon 75, causing RNA decay or protein truncation35
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pathogenesis. CSTB encodes the cystatin B protein, a
widely expressed reversible inhibitor of cysteine protease
that is thought to have lysosome-associated physiological
functions.Cysteine protease inhibitors play an important
role in controlling endogenous and exogenous protease
activities,protecting organisms from protein degradation.
Cystatin B is thought to be involved in the maintenance of
normal neuronal structure, and loss of its expression in
mouse models caused increased expression of genes
involved in proteolysis,apoptosis,and glial activation.Thus
neuronal loss by apoptosis and gliosis seems to be an
important mechanism in the pathogenesis of EPM1.
37,38
There is also mounting evidence that Cystatin B might
have an additional function in the cerebellum unrelated to
its role in protease inhibition.Coprecipitation experiments
showed that cystatin B interacts with different cerebellum-
expressed proteins that are not functioning as proteases.
What this additional role of cystatin B might be remains
unknown so far.
39
Myoclonic epilepsy and 
ragged-red fiber disease 
Mitochondria are small intracellular organelles that pos-
sess their own circular DNA molecules (mtDNA).
Mutations in mtDNA that interfere with or even abolish
the ability of mitochondria to perform their role in aer-
obic respiration are known to cause a wide spectrum of
different disorders.They all have in common a pattern of
symptoms that predominantly affect tissues with a high
dependence on oxidative metabolism,such as brain,mus-
cle,and heart.The clinical manifestations of mitochon-
drial disorders are extremely heterogeneous;they range
from lesions of single tissues to severe impairments
including myopathies,encephalomyopathies,cardiomy-
opathies,or complex multisystem syndromes.
40,41A typi-
cal example of such a mitochondrial disorder is MERRF,
another member of the group of progressive myoclonus
epilepsies.MERRF is characterized by myoclonus,gen-
eralized epileptic seizures, myopathy, and slowly pro-
gressive dementia.Additional symptoms can be hearing
loss,ataxia,and lipomatosis.Histopathological analysis
of muscle bioptic material typically shows ragged-red
fibers and abnormal mitochondria with concentric
cristae.Age of onset and clinical severity differ widely
from patient to patient, even between siblings. This is
mainly explained by heteroplasmy,ie,each patient inher-
its a different mixture of normal and mutated mitochon-
dria from his or her mother (there is no paternal inheri-
tance of mitochondria since sperm mitochondria that
enter the oocyte are “digested”).The most commonly
found MERRF mutation is mt8344A>G that affects the
tRNALysine gene within the mtDNA.
42 Due to the het-
eroplasmatic nature of the disorder the molecular diag-
nosis from blood not always reliably detects the under-
lying mutation. Skeletal muscle frequently has the
highest percentage of mutated mtDNA molecules in
MERRF patients, and this percentage correlates best
with the clinical severity of the disorder.
43 Muscle biopsy
is therefore the first choice to obtain material for diag-
nostic mutation analysis.Close to 150 pathogenic muta-
tions in 21 of the 22 mitochondrial tRNA genes have
been described up to now,and 50% of these mutations
are located in either one of three tRNA genes,
tRNA
Leu(UUR),t R N A
LYS, or tRNA
Ile. Mutations in tRNA
genes might have different pathological effects,including
structural perturbances of the three-dimensional tRNA
structure,reduced or abolished binding capacity to trans-
lation factors such as the elongation factor EF-Tu, or
impairment of tRNA maturation.All of these mutations
affect the essential role tRNA genes have in the synthe-
sis of proteins involved in energy metabolism, causing
various neuromuscular and neurodegenerative disorders.
Neuronal ceroid lipofuscinoses 
The different subtypes of neuronal ceroid lipofuscinoses
(CLN, or NCL) are (with one exception) autosomal
recessively inherited neurodegenerative disorders
belonging to the group of lysosomal storage diseases.
44
The childhood forms of CLN are characterized by men-
tal and motor deterioration,as well as progressive loss of
vision, myoclonic, tonic-clonic, and atypical absence
seizures,and premature death,while dementia presents
as the main feature in the rare adult forms of CLN.The
human CLNs are presently classified into eight main
genetic forms (CLN1–8).The infantile subtype of CLN,
Santavuori-Haltia-Hagberg disease (CLN1),occurs pri-
marily in the Finish population.The classical late-infan-
tile form of CLN,Jansky-Bielschowsky disease (CLN2),
starts at age 2 to 4 years with myoclonus and seizures.
There are at least three additional subtypes that are clas-
sified as variants of late infantile CLN.These include the
Finnish variant (CLN5),the CLN6 variant of late infan-
tile CLN,and the Turkish variant of CLN (CLN8).The
CLN8 gene also causes Northern epilepsy or progressiveepilepsy with mental retardation,an autosomal recessive
epilepsy of childhood onset that is only found in parts of
northern Finland.Juvenile-onset CLN (Batten disease,
Vogt-Spielmeyer disease) is the most common neurode-
generative disorder of childhood,with an age of onset at
5 to 10 years.Kufs disease or adult CLN (CLN4) is dis-
tinguished clinically from the infantile and juvenile sub-
types by onset of progressive myoclonus epilepsy in
adulthood and by the absence of ocular involvement.
Additionally,a few rare forms exist that have not been
genetically assigned yet,including congenital NCL and
dominantly inherited adult onset NCL (Parry disease,
Table III).
45-48
Characteristic features of CLN are an accumulation of aut-
ofluorescent,periodic acid-Schiff- and Sudan black B-pos-
itive granules in the cytoplasm of most nerve cells,astro-
cytic proliferation and hypertrophy,and progressive and
remarkably selective neuronal degeneration and loss.
49The
storage cytosomes characteristic for CLN mainly contain
of two hydrophobic proteins, the sphingolipid activator
proteins A and D (infantile form of CLN) or the subunit
c of mitochondrial ATP synthase (late infantile and juve-
nile CLN).
50The CLN1 and CLN2 genes code for the sol-
uble lysosomal enzymes PPT1 and tripeptidyl peptidase 1
(TPP1),whereas CLN3,CLN6,CLN8 and,possibly,CLN5
are transmembrane proteins of largely unknown functions.
It is still unclear how a group of genes as heterogeneous
as the CLN genes can cause such a remarkably uniform
morphological phenotype characterized by intraneuronal
accumulation of hydrophobic proteins.Different mecha-
nisms including both apoptotic and excitotoxic processes
are discussed,but the exact nature of the pathophysiolog-
ical pathways underlying the different CLN subtypes
remain to be elucidated.
51
Neuronal migration disorders
The migration and maturation of neurons,synapses,and
cortical neuronal networks during embryonal and fetal
development is a sequential process composed of differ-
ent steps that are regulated by genetic and environmen-
tal factors.
52The cortical neurons are formed in the neu-
roepithelium of the ventricular zone,and then migrate
considerable distances to reach their final position in the
cortex.In humans,neuronal migration in the cortex starts
at approximately 7 weeks of gestation from the prolifer-
ative ventricular zone.The radially migrating neurons as
well as the nonradially (tangential) migrating future
interneurons are guided by glial fibers through an inter-
action of adhesion molecules,trophic factors,and guid-
ance molecules.Any disturbances (genetic or environ-
mental) of these complicated migration and matu-rating
processes have the potential to cause severe neurologi-
cal disorders with various symptoms, including mental
retardation and epilepsy.Genetic neuronal migration dis-
orders include different lissencephaly syndromes and
subcortial band heterotopia, cobblestone dysplasia (a
term describing the bumpy surface of the brain that is
caused by ectopic neurons and gliovascular prolifera-
tion), and different gray matter heterotopia disorders
(see also the article by Leventer et al in this issue,p 47).
Conclusion
Although the number of already known epilepsy genes
is impressive,they probably represent only the tip of the
proverbial iceberg.A roughly estimated 50% of all genes
are,at least during fetal development,expressed in brain
and might therefore be regarded as candidates for
Basic research
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Table III. Ceroid lipofuscinosis subtypes in humans. AR, autosomal recessive; AD autosomal dominant; INCL, infantile CLN; LINCL, late infantile CLN;
ANCL, adult NCL; vLINCL, variant late infantile CLN; NK, not known
CLN subtype Eponym Gene Chromosome Inheritance
CLN1 Haltia–Santavuori disease, INCL CLN1 1p32 AR
CLN2 Jansk˘-Bielschowsky disease, LINCL CLN2 11p15 AR
CLN3 Spielmeyer-Sjögren disease CLN3 16p12 AR
CLN4a Kufs disease, ANCL NK NK AR
CLN5 vLINCL Finnish CLN5 13q22 AR
CLN6 Lake-Cavanagh disease, vLINCL CLN6 15q21–23 AR
CLN7 vLINCL Turkish NK NK AR
CLN8 Northern epilepsy, progressive epilepsy with mental retardation CLN8 8p32 AR
CLN10 Congenital  CLN CTSD 11p15.5 AR
CLN4b Parry  disease NK NK ADseizure disorders. Furthermore, recent research has
shown that alterations of genomic DNA copy number
and gene regulatory elements are likely to be as impor-
tant for human disorders as mutations that directly affect
genes.
53 In the future,whole-genome screening methods
such as array-based comparative genomic hybridization
(aCGH) or genome-wide single nucleotide polymor-
phism (SNP) analysis will become important tools for the
identification of genetic alterations with potential appli-
cation to common forms of human epilepsy. ❏
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Genética y epilepsia
El término “epilepsia” describe un grupo hetero-
géneo de trastornos, la mayoría de los cuales son
causados por interacciones entre algunos o incluso
muchos genes, y  factores ambientales. Son bas-
tante más raras las epilepsias genéticas que se
deben a mutaciones de un gen único o aberracio-
nes cromosómicas estructurales definidas, como las
microdeleciones. El descubrimiento de algunos de
los genes que están a la base de estas raras epilep-
sias genéticas ya ha contribuido considerablemente
a la comprensión de los mecanismos básicos en la
epileptogénesis. El progreso que se ha llevado a
cabo en los últimos 15 años en la genética de la epi-
lepsia está aportando nuevas posibilidades diag-
nósticas y terapéuticas. En este artículo se revisan,
a modo de ejemplo, diferentes epilepsias genéticas
para demostrar las diversas vías que pueden llevar
desde los genes a las convulsiones. 
Génétique et épilepsie
Le terme « épilepsie » décrit un groupe hétérogène
de troubles dont la plupart sont dus à des interac-
tions entre quelques, ou même de nombreux gènes
et des facteurs environnementaux. Plus rares sont
les épilepsies génétiques qui sont dues à des muta-
tions d’un seul gène ou à des aberrations chromo-
somiques de structure définies comme les microdé-
létions. Notre compréhension des mécanismes de
base de l’épileptogenèse a déjà été considérable-
ment améliorée par la découverte de plusieurs de
ces gènes impliqués dans ces épilepsies génétiques
peu répandues. Les progrès effectués ces 15 der-
nières années dans la génétique de l’épilepsie
ouvrent de nouvelles perspectives de diagnostic et
de traitement. Dans cet article, nous passons en
revue différentes épilepsies génétiques comme
exemples illustrant les différentes voies qui mènent
des gènes à l’apparition d’une crise comitiale.
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